In a bid to "advance opportunities" in cell and gene therapy, the FDA intends to unveil additional new policy guidance and other progress made in its drug development framework this year.
In a bid to "advance opportunities" in cell and gene therapy, the FDA intends to unveil additional new policy guidance and other progress made in its drug development framework this year.
A surge in cell and gene therapy trials - an increase of 37% since 2017 - highlights the UK’s leading position as a developmental hub in this innovative industry, according to the Cell and Gene Therapy Catapult.